Prediction of Thorough QT study results using action potential simulations based on ion channel screens

Journal of Pharmacological and Toxicological Methods

Volumn 70, Issue 3, 2014, Pages 246-254

  Mirams, Gary R ^a   Davies, Mark R ^b   Brough, Stephen J ^c   Bridgland Taylor, Matthew H ^b   Cui, Yi ^c   Gavaghan, David J ^a   Abi Gerges, Najah ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Action potential; Cardiac safety; Compound screening; High throughput; Mathematical model; Methods; Thorough QT

Indexed keywords

CALCIUM CHANNEL CAV1.2; ION CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KV4.3; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); FEASIBILITY STUDY; FREQUENCY MODULATION; HEART MUSCLE POTENTIAL; HEART VENTRICLE WALL; ION CURRENT; PATCH CLAMP TECHNIQUE; PREDICTION; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIMULATION; STEADY STATE; ACTION POTENTIAL; ADVERSE EFFECTS; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ELECTROCARDIOGRAPHY; HUMAN; LONG QT SYNDROME; METABOLISM;

ACTION POTENTIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HUMANS; ION CHANNELS; LONG QT SYNDROME;

EID: 84926466778     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2014.07.002     Document Type: Article

References (38)

1. Beattie K., Luscombe C., Williams G., Munoz-Muriedas J., Gavaghan D., Cui Y., et al. Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. Journal of Pharmacological and Toxicological Methods 2013, 68(1):88-96.
2. Brennan T., Fink M., Rodriguez B. Multiscale modelling of drug-induced effects on cardiac electrophysiological activity. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2009, 36(1):62-77.
3. Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. Journal of Internal Medicine 2006, 259(1):70-80.
4. Cooper J., Corrias A., Gavaghan D., Noble D. Considerations for the use of cellular electrophysiology models within cardiac tissue simulations. Progress in Biophysics and Molecular Biology 2011, 107(1):74-80.
5. Cooper J., Mirams G., Niederer S. High-throughput functional curation of cellular electrophysiology models. Progress in Biophysics and Molecular Biology 2011, 107(1):11-20.
6. Di Veroli G.Y., Davies M.R., Zhang H., Abi-Gerges N., Boyett M.R. High-throughput screening of drug binding dynamics to hERG improves early drug safety assessment. American Journal of Physiology. Heart and Circulatory Physiology Oct. 2012, 304(1):H104-H117.
7. Elkins R., Davies M., Brough S., Gavaghan D., Cui Y., Abi-Gerges N., et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment. Journal of Pharmacological and Toxicological Methods 2013, 68(1):112-122.
8. Fletcher K., Shah R.R., Thomas A., Tobin F., Rodríguez B., Mirams G.R., et al. Novel approaches to assessing cardiac safety-proceedings of a workshop: Regulators, industry and academia discuss the future of in silico cardiac modelling to predict the proarrhythmic safety of drugs. Drug Safety 2011, 34(5):439-443.
9. Gillie D.J., Novick S.J., Donovan B.T., Payne L.A., Townsend C. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG. Journal of Pharmacological and Toxicological Methods 2013, 67(1):33-44.
10. Gintant G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical qt prolongation. Pharmacology & Therapeutics 2011, 129(2):109-119.
11. Gintant G. Ions, equations and electrons: The evolving role of computer simulations in cardiac electrophysiology safety evaluations. British Journal of Pharmacology 2012, 167(5):929-931.
12. Gintant G.A., Gallacher D.J., Pugsley M.K. The 'overly-sensitive' heart: Sodium channel block and QRS interval prolongation. British Journal of Pharmacology 2011, 164(2):254-259.
13. Grandi E., Pasqualini F., Bers D. A novel computational model of the human ventricular action potential and Ca transient. Journal of Molecular and Cellular Cardiology 2010, 48:112-121.
14. Hill A.V. Proceedings supplement: The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. The Journal of Physiology 1910, 40:iv-vii. (Suppl.).
15. Hindmarsh A., Brown P., Grant K., Lee S., Serban R., Shumaker D., et al. SUNDIALS: Suite of nonlinear and differential/algebraic equation solvers. ACM Transactions on Mathematical Software (TOMS) 2005, 31(3):363-396.
16. ICH E14: The clinical evaluation of QT/QTc Interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Tech. rep 2005, (URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf).
17. ICH S7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Tech. rep 2005, (URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf).
18. Kleiman R.B., Shah R.R., Morganroth J. Replacing the Thorough QT Study: Reflections of a baby in the bath water. British Journal of Clinical Pharmacology 2014, 78(2):195-201.
19. Kramer J., Obejero-Paz C.A., Myatt G., Kuryshev Y.A., Bruening-Wright A., Verducci J.S., et al. MICE models: Superior to the HERG model in predicting Torsade de Pointes. Scientific Reports 2013, 3:2100.
20. Lacerda A., Kuryshev Y., Chen Y., Renganathan M., Eng H., Danthi S., et al. Alfuzosin delays cardiac repolarization by a novel mechanism. Journal of Pharmacology and Experimental Therapeutics 2008, 324(2):427-433.
21. Lloyd C., Lawson J., Hunter P., Nielsen P. The CellML model repository. Bioinformatics 2008, 24(18):2122-2123.
22. Mirams G., Arthurs C., Bernabeu M., Bordas R., Cooper J., Corrias A., et al. Chaste: An open source C++ library for computational physiology and biology. PLoS Computational Biology 2013, 9(3):e1002970.
23. Mirams G., Cui Y., Sher A., Fink M., Cooper J., Heath B., et al. Simulation of the effect of compounds on multiple ion channels provides improved early prediction of their clinical torsadogenic risk. Cardiovascular Research 2011, 91(1):53-61.
24. Mirams G.R., Davies M.R., Cui Y., Kohl P., Noble D. Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing. British Journal of Pharmacology 2012, 167(5):932-945.
25. Mirams G.R., Noble D. Is it time for in silico simulation of drug cardiac side effects?. Annals of the New York Academy of Sciences 2011, 1245:44-47.
26. Moreno J.D., Zhu Z.I., Yang P.-C.C., Bankston J.R., Jeng M.-t.T., Kang C., et al. A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms. Science Translational Medicine 2011, 3(98):98ra83.
27. to) expression and regulation. Journal of Molecular and Cellular Cardiology 2010, 48(1):12-25.
28. O'Hara T., Virág L., Varró A., Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation. PLoS Computational Biology 2011, 7(5):e1002061.
29. Pollard C.E., Gerges N.A., Bridgland-Taylor M.H., Easter A., Hammond T.G., Valentin J.P. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. British Journal of Pharmacology 2010, 159(1):12-21.
30. Quinn T., Granite S., Allessie M.A., Antzelevitch C., Bollensdorff C., Bub G., et al. Minimum information about a Cardiac Electrophysiology Experiment (MICEE): Standardised reporting for model reproducibility, interoperability, and data sharing. Progress in Biophysics and Molecular Biology 2011, 107(1):4-10.
31. Redfern W., Carlsson L., Davis A., Lynch W., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58(1):32-45.
32. Sager P.T., Gintant G., Turner J.R., Pettit S., Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. American Heart Journal 2014, 167(3):292-300.
33. Sanguinetti M., Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440(7083):463-469.
34. Severi S., Corsi C., Rocchetti M., Zaza A. Mechanisms of beta-adrenergic modulation of I(Ks) in the guinea-pig ventricle: Insights from experimental and model-based analysis. Biophysical Journal 2009, 96(9):3862-3872.
35. Shannon T.R., Wang F., Puglisi J., Weber C., Bers D.M. A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. Biophysical Journal 2004, 87(5):3351-3371.
36. Silva J., Rudy Y. Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. Circulation 2005, 112(10):1384-1391.
37. ten Tusscher K., Noble D., Noble P., Panfilov A. A model for human ventricular tissue. American Journal of Physiology. Heart and Circulatory Physiology 2004, 286(4):1573-1589.
38. ten Tusscher K., Panfilov A. Alternans and spiral breakup in a human ventricular tissue model. American Journal of Physiology. Heart and Circulatory Physiology 2006, 291(3):1088-1100.